Belgium: Defensive actions in UPC and national courts

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Belgium: Defensive actions in UPC and national courts

The opt‐out possibility offered by Article 83 UPCA pays lots of attention to the choices patentees are facing with regards to their filing strategy. We focus here on defensive strategies in the new legislative framework, in particular on actions before national courts.

Coexistence between the UPC and national jurisdictions during the transitional period is governed by the UPCA and by the Brussels Regulation (Recast) (EU) 1215/2012.

Article 83.3 UPCA establishes the right to opt‐out (completely) of the UPC.

Article 83.4 UPCA further stipulates that unless an action has already been brought before a national court, proprietors of or applicants for European patents who made use of the opt‐out in accordance with paragraph 3 shall be entitled to withdraw their opt‐out at any moment.

Thus, if an invalidity action before a national court exists, patentees will not be able to use the UPC at all, including an infringement action.

Is such a legal effect compatible with the Brussels Regulation? Not sure. It is true that under the Regulation, the court first seized retains jurisdiction when the same action, involving the same parties, is subsequently filed in another EU court. Consequently, the existence of an invalidity action in a national court should not prevent the use of the UPC for an infringement action.

In any event, Article 83 deals with the specific opt‐out context. But what about the more general context, namely the impact of an existing action before a national court, where no opt‐out has been requested?

Furthermore, what is the impact of actions before national courts pending at the time of the UPC inception?

These uncertainties make it difficult for parties to implement a defensive strategy. Is it worth investing in an invalidity action in a national court, before entry into force of the UPC? Assuming such an action impacts patentees' choices at all, will it completely prevent the use of the UPC or only preclude the use of the UPC for a nullity action?

Canonici

Jean‐Jacques Canonici


Gevers & OresHolidaystraat, 5B-1831 Diegem - BrusselsBelgiumTel: +32 2 715 37 11Fax: +32 2 715 37 00www.gevers.eu

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article